Skip to main content

Homatropine / hydrocodone Pregnancy and Breastfeeding Warnings

Medically reviewed by Last updated on Jan 23, 2023.

Homatropine / hydrocodone is also known as: Hycodan, Hydromet, Hydromide, Hydropane, Hydrotropine, Tussigon

Homatropine / hydrocodone Pregnancy Warnings

Animal studies have not been conducted with this combination product, and there are no adequate and well-controlled studies in pregnant women.

Animal studies with subcutaneous hydrocodone have shown teratogenicity when given during organogenesis at doses approximately 70 times the maximum recommended human dose (MRHD). Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. Babies born to mothers taking opioids regularly during pregnancy may become physically dependent. Opioids can prolong labor by temporarily reducing the strength, duration, and frequency of uterine contractions, however this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Opioids given to mothers shortly before delivery may produce some degree of respiratory depression in the newborn, especially if high doses are used. Chronic use of opioids may reduce fertility in males and females of reproductive potential; it is unknown if these effects are reversible.

Homatropine: Animal studies are not available.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

Use is not recommended, including during or immediately prior to labor

US FDA pregnancy category: Not assigned

-Prolonged use of opioids during pregnancy may cause neonatal withdrawal syndrome and physical dependence in the neonate.
-Neonatal withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea, and failure to gain weight.
-The onset, duration, and severity of neonatal withdrawal syndrome vary with the specific opioid used, duration of use, timing and amount of last maternal use, and the newborn's rate of drug elimination.
-Observe newborns for symptoms of neonatal withdrawal syndrome and manage appropriately.
-An opioid antagonist (e.g. naloxone) should be available for reversal of opioid-induced respiratory depression in the neonate.
-Monitor neonates exposed to opioids during labor for excess sedation and respiratory depression.
-Advise women of the risk of neonatal withdrawal syndrome and ensure that appropriate treatment will be available.

See references

Homatropine / hydrocodone Breastfeeding Warnings

Use is not recommended.

Excreted into human milk: Unknown (homatropine); Yes (hydrocodone)

-This drug has a potential for serious adverse reactions, including excess sedation, respiratory depression, and death.
-Breastfed infants should be closely monitored for excess sedation, respiratory depression, and irritability.
-Withdrawal symptoms can occur in breastfed infants when maternal opioids are stopped or breastfeeding is stopped.

Hydrocodone: Case reports have shown variable hydrocodone and hydromorphone (an active metabolite) levels in breast milk with use of immediate release hydrocodone to nursing mothers in the early postpartum period with relative infant doses of hydrocodone ranging between 1.4 and 3.7%. There are case reports of excessive sedation and respiratory depression in breastfed infants exposed to hydrocodone.

Homatropine: No information is currently available on homatropine's presence in breast milk or effects on lactation. Published literature suggests homatropine may decrease milk production due to its anticholinergic effect.

See references

References for pregnancy information

  1. "Product Information. Homatropine Methylbromide-Hydrocodone (homatropine-hydrocodone)." KVK-Tech Inc (2017):

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network." (2013):
  2. "Product Information. Homatropine Methylbromide-Hydrocodone (homatropine-hydrocodone)." KVK-Tech Inc (2017):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.